A China Phase I, Open Label, Multi-Center, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors

Trial Profile

A China Phase I, Open Label, Multi-Center, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Pamiparib (Primary)
  • Indications Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors BeiGene
  • Most Recent Events

    • 16 Apr 2018 According to a BeiGene Ltd. media release, resultes were presented at the 2018 American Association for Cancer Research (AACR) Annual Meeting,
    • 16 Apr 2018 Results published in the BeiGene Ltd Media Release
    • 21 Dec 2016 According to a BeiGene Ltd. media release, Professor Binghe Xu from The Chinese Academy of Medical Sciences Cancer Hospital is the principal investigator of the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top